Literature DB >> 12556682

CD4-dependent and CD4-independent HIV-2: consequences for neutralization.

Elaine R Thomas1, Christine Shotton, Robin A Weiss, Paul R Clapham, Aine McKnight.   

Abstract

BACKGROUND: HIV-2 is less pathogenic than HIV-1. In contrast to HIV-1, many isolates of HIV-2, including primary isolates, can infect cells independently of CD4.
OBJECTIVE: To compare the sensitivity of CD4-dependent and CD4-independent isolates of HIV-2 to antibody-mediated neutralization.
METHODS: The neutralization sensitivity of CD4-dependent and CD4-independent molecular clones of HIV-2 to a panel of HIV-2-positive serum samples was tested. Monoclonal antibodies to various epitopes across the viral envelope were used to determine whether a specific epitope conferred neutralization sensitivity. Neutralization sensitivity of primary isolates of HIV-2 able to infect in the absence of cellular CD4 was also investigated. Antibody binding to sensitive and resistant envelopes was analysed using enzyme-linked immunosorbent assay and flow cytometry.
RESULTS: CD4-independent ROD B was highly sensitive to neutralization by HIV-2-positive sera compared with the CD4-dependent isolate ROD A. Induction of ROD A to infect CD4-negative cells by soluble CD4 rendered it equally sensitive to antibody neutralization. Similarly, primary X4, R5 or dual-tropic isolates of HIV-2 were significantly more susceptible to neutralization when utilizing a CD4-independent route of infection. Neutralization sensitivity was not epitope specific but several conformation-dependent antibodies accentuated this phenotype. Antibody binding to monomeric or oligomeric envelope did not correlate with neutralization sensitivity.
CONCLUSIONS: HIV-2 isolates utilizing a CD4-independent route of infection are more sensitive to antibody-mediated neutralization. Cellular CD4 may protect HIV-2 from neutralization. This sensitivity to neutralization may, in part, explain the lower virus load and slower progression to disease in HIV-2-infected individuals.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12556682     DOI: 10.1097/00002030-200302140-00002

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  16 in total

1.  Potent intratype neutralizing activity distinguishes human immunodeficiency virus type 2 (HIV-2) from HIV-1.

Authors:  Gülsen Ozkaya Sahin; Birgitta Holmgren; Zacarias da Silva; Jens Nielsen; Salma Nowroozalizadeh; Joakim Esbjörnsson; Fredrik Månsson; Sören Andersson; Hans Norrgren; Peter Aaby; Marianne Jansson; Eva Maria Fenyö
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

2.  Residues in the gp41 Ectodomain Regulate HIV-1 Envelope Glycoprotein Conformational Transitions Induced by gp120-Directed Inhibitors.

Authors:  Beatriz Pacheco; Nirmin Alsahafi; Olfa Debbeche; Jérémie Prévost; Shilei Ding; Jean-Philippe Chapleau; Alon Herschhorn; Navid Madani; Amy Princiotto; Bruno Melillo; Christopher Gu; Xin Zeng; Youdong Mao; Amos B Smith; Joseph Sodroski; Andrés Finzi
Journal:  J Virol       Date:  2017-02-14       Impact factor: 5.103

3.  Cloning, expression, and purification of HIV-2 gp125: A target for HIV vaccination.

Authors:  Samer Sourial; Anette Wärnmark; Charlotta Nilsson; Ewa Björling; Adnane Achour; Robert A Harris
Journal:  Mol Biotechnol       Date:  2005-06       Impact factor: 2.695

4.  Expanded tropism and altered activation of a retroviral glycoprotein resistant to an entry inhibitor peptide.

Authors:  Sean M Amberg; Robert C Netter; Graham Simmons; Paul Bates
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

5.  A single amino acid change and truncated TM are sufficient for simian immunodeficiency virus to enter cells using CCR5 in a CD4-independent pathway.

Authors:  A Bonavia; B T Bullock; K M Gisselman; B J Margulies; J E Clements
Journal:  Virology       Date:  2005-10-10       Impact factor: 3.616

Review 6.  Chemokine receptors and co-stimulatory molecules: unravelling feline immunodeficiency virus infection.

Authors:  Brian J Willett; Margaret J Hosie
Journal:  Vet Immunol Immunopathol       Date:  2008-01-19       Impact factor: 2.046

7.  Effect of complement on HIV-2 plasma antiviral activity is intratype specific and potent.

Authors:  Gülşen Özkaya Şahin; Birgitta Holmgren; Enas Sheik-Khalil; Zacarias da Silva; Jens Nielsen; Salma Nowroozalizadeh; Fredrik Månsson; Hans Norrgren; Peter Aaby; Eva Maria Fenyö; Marianne Jansson
Journal:  J Virol       Date:  2012-10-17       Impact factor: 5.103

8.  Lv2, a novel postentry restriction, is mediated by both capsid and envelope.

Authors:  Christian Schmitz; David Marchant; Stuart J D Neil; Keith Aubin; Sandra Reuter; Matthias T Dittmar; Aine McKnight
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

9.  Structure of an HIV-2 gp120 in Complex with CD4.

Authors:  Yunji W Davenport; Anthony P West; Pamela J Bjorkman
Journal:  J Virol       Date:  2015-11-25       Impact factor: 5.103

10.  Antagonism to and intracellular sequestration of human tetherin by the human immunodeficiency virus type 2 envelope glycoprotein.

Authors:  Anna Le Tortorec; Stuart J D Neil
Journal:  J Virol       Date:  2009-09-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.